IDSA announces presenters and order of presentation

Byldoadmin

 

 

Below is the final order of presenters:

  1. Tina Garcia (patient advocate )
  2. Lorraine Johnson (patient advocate)
  3. Daniel Cameron (physician-scientist)
  4. Phillip Baker (physician-scientist)
  5. Ben Luft (physician-scientist)
  6. Allison Delong (scientist)
  7. Barbara Johnson (physician-scientist)
  8. David Volkman (physician-scientist)
  9. Sam Donta (physician-scientist)
  10. Eugene Shapiro (physician-scientist)
  11. Brian Fallon (physician-scientist)
  12. Sunil Sood (physician-scientist)
  13. Ken Liegner (physician-scientist)
  14. Allen Steere (physician-scientist)
  15. Steven Phillips (physician-scientist)
  16. Art Weinstein (physician-scientist)
  17. Raphael Stricker (physician-scientist)
  18. Gary Wormser (physician-scientist)

 

 

Similar Posts

  • LYMEPOLICYWONK: NIH Tick Feeding Study Safety Risk Update

    We recently received a response from the NIH regarding our concerns about the NIH tick feeding study and the risk of tickborne infections from the larval ticks that researchers intend to place on patients to feed. We have written the NIH about this several times. Our latest letter focused on the newly identified pathogen, Borrelia miyamotoi, which can be transmitted to larval ticks through the mother's eggs. We asked the NIH to tell us what bacteria they test for in the larval ticks to ensure that patients in the study are not at risk. According to the NIH, the following pathogens are screened for: Borrelia burgdorferi, Babesia microti, Anaplasma phagocytophilum, Borrelia miyamotoi, Bartonella spp, Rickettsia sp., deer tick viruses and orbiviruses. We are glad to see that these pathogens are being screened for but remain concerned that unidentified pathogens nevertheless place patients at risk in the study.

  • LYMEPOLICYWONK: Lyme Patients and Insurance Appeals

    Lyme disease patients have trouble with insurance coverage. They have trouble getting health insurance if they have ever had Lyme disease, on the one hand. On the other hand, they have trouble getting the disease treated because insurers rely on the IDSA guidelines to take a "free pass" on treatment reimbursements. This is an area that is clearly governed by something other than providing quality health care to patients. Have you ever wondered what happens–really happens–when Lyme patient appeal an insurance denial? What happens is we succeed 9% of the time, while other diseases succeed 40% of the time. What is going on here? How can that be?

  • LYMEPOLICYWONK: Diane Blanchard’s Comments to IOM Committee

    I am posting the written speeches of those who commented during the public comment period of the IOM. The speech below is that of Diane Blanchard, Co-President of Time for Lyme, who addressed the issue of scientific bias and the importance of separating fact from opinion. She also emphasized that it was important to listen to patients drawing the parallel to the discovery of Lyme by Polly Murphy, a mother in a local community. Her testimony is available as a downloadable pdf by clicking the link at the bottom of this blog post.

  • |

    LYMEPOLICYWONK: Lyme Vaccinations: Safety First

    Dr. Stricker and I published a letter to the editor on Lyme vaccines in Lancet. The letter responds to an article by employees of Baxter, which has a vaccine in development. The article by Baxter employees in support of a new vaccine was published with an editorial by Dr. Lantos, the new Lyme spokesman for the IDSA. Both the Baxter article and the Lantos editorial make short shrift of patient vaccine safety concerns, which Lantos describes as “largely unsubstantiated”. Dr. Stricker and I note that the first vaccines sparked a class action lawsuit from patients harmed by the vaccines. In the end, of course, the vaccine was pulled by the manufacturer. We note that “by withdrawing LYMErix when it did, the manufacturer avoided releasing phase 4 post-marketing data that probably would have shown increased side-effects related to the vaccine. The data have never been disclosed.” We conclude that given this sketchy past, any new vaccine will need to be forthright about safety issues. The dismissive attitude toward patient safety reflected in the Baxter article and the Lantos editorial serve only to increase patient distrust. Because vaccinations are given to a healthy population, our first priority is to make sure they are safe. Our letter to the editor is available open access for readers.

  • LYMEPOLICYWONK: Meeting with Dr. Ben Beard of the CDC–The Importance of Dialogue and Lingering Concerns

    Dr. Ben Beard of the CDC met with directors of CALDA on March 10 as part of an effort to reach out to Lyme patient groups across the nation. After meeting with CALDA, he attended the regularly scheduled meeting of the California State Lyme Disease Advisory Committee, which was created under legislation sponsored by CALDA to encourage dialogue with the California Department of Public Health. If you have not met Ben Beard before, he is both engaging and likable and has a measured tone. CALDA believes that respectful dialogue is essential to moving forward for the Lyme community, and we are pleased with this first step. We also believe that patients need to be meaningful participants in any solution for Lyme disease. We raised a number of concerns about the CDC's Lyme disease policies, including the need to treat to cure disease, the education of physicians and government funding of research. Here are the issues that loom large.